Covadonga Pañeda
Directeur des opérations chez ALTAMIRA THERAPEUTICS LTD.
Profil
Covadonga Pañeda is currently the Chief Operating Officer at Altamira Therapeutics Ltd.
Prior to this role, she served as the Director-Development at LiMM Therapeutics SA from 2020 to 2022.
From 2011 to 2018, she worked at Sylentis SA as the Manager-Research & Development.
Dr. Pañeda holds a doctorate degree from Universidad Autónoma de Madrid.
Postes actifs de Covadonga Pañeda
| Sociétés | Poste | Début |
|---|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Directeur des opérations | 01/01/2023 |
Anciens postes connus de Covadonga Pañeda
| Sociétés | Poste | Fin |
|---|---|---|
LiMM Therapeutics SA
 LiMM Therapeutics SA Financial ConglomeratesFinance LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France. | Corporate Officer/Principal | 01/04/2022 |
Sylentis SA
 Sylentis SA BiotechnologyHealth Technology Sylentis SA develops new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. The company is headquartered in Madrid, Spain. | Directeur Technique/Scientifique/R&D | 01/06/2018 |
Formation de Covadonga Pañeda
| Universidad Autónoma de Madrid | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Sylentis SA
Sylentis SA BiotechnologyHealth Technology Sylentis SA develops new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. The company is headquartered in Madrid, Spain. | Health Technology |
LiMM Therapeutics SA
LiMM Therapeutics SA Financial ConglomeratesFinance LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France. | Finance |
